These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 33942482)
21. Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction. Oliver J; Garcia-Aranda M; Chaves P; Alba E; Cobo-Dols M; Onieva JL; Barragan I Semin Cancer Biol; 2022 Aug; 83():584-595. PubMed ID: 33757849 [TBL] [Abstract][Full Text] [Related]
22. Whole-genome bisulfite sequencing analysis of circulating tumour DNA for the detection and molecular classification of cancer. Gao Y; Zhao H; An K; Liu Z; Hai L; Li R; Zhou Y; Zhao W; Jia Y; Wu N; Li L; Ying J; Wang J; Xu B; Wu Z; Tong Z; He J; Sun Y Clin Transl Med; 2022 Aug; 12(8):e1014. PubMed ID: 35998020 [TBL] [Abstract][Full Text] [Related]
23. Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer. Yeung KT; More S; Woodward B; Velculescu V; Husain H Mol Diagn Ther; 2017 Aug; 21(4):375-384. PubMed ID: 28337711 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer. Roy D; Tiirikainen M Trends Cancer; 2020 Feb; 6(2):78-81. PubMed ID: 32061307 [TBL] [Abstract][Full Text] [Related]
25. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Liang W; Zhao Y; Huang W; Gao Y; Xu W; Tao J; Yang M; Li L; Ping W; Shen H; Fu X; Chen Z; Laird PW; Cai X; Fan JB; He J Theranostics; 2019; 9(7):2056-2070. PubMed ID: 31037156 [No Abstract] [Full Text] [Related]
26. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. Giannopoulou L; Kasimir-Bauer S; Lianidou ES Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534 [TBL] [Abstract][Full Text] [Related]
27. Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. van der Pol Y; Mouliere F Cancer Cell; 2019 Oct; 36(4):350-368. PubMed ID: 31614115 [TBL] [Abstract][Full Text] [Related]
28. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317 [TBL] [Abstract][Full Text] [Related]
29. Cell-free DNA as a post-treatment surveillance strategy: current status. Burgener JM; Rostami A; De Carvalho DD; Bratman SV Semin Oncol; 2017 Oct; 44(5):330-346. PubMed ID: 29580435 [TBL] [Abstract][Full Text] [Related]
30. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection. Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556 [TBL] [Abstract][Full Text] [Related]
31. Circulating Tumor DNA in the Management of Early-Stage Breast Cancer. Vlataki K; Antonouli S; Kalyvioti C; Lampri E; Kamina S; Mauri D; Harissis HV; Magklara A Cells; 2023 Jun; 12(12):. PubMed ID: 37371043 [TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications. Croessmann S; Park BH Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964 [TBL] [Abstract][Full Text] [Related]
33. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies. Valpione S; Campana L Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235 [TBL] [Abstract][Full Text] [Related]
34. Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA. Lyskjær I; Kara N; De Noon S; Davies C; Rocha AM; Strobl AC; Usher I; Gerrand C; Strauss SJ; Schrimpf D; von Deimling A; Beck S; Flanagan AM Eur J Cancer; 2022 Jun; 168():1-11. PubMed ID: 35421838 [TBL] [Abstract][Full Text] [Related]
35. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Cheng F; Su L; Qian C Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063 [TBL] [Abstract][Full Text] [Related]
36. DNA methylation and breast cancer: A way forward (Review). Vietri MT; D'Elia G; Benincasa G; Ferraro G; Caliendo G; Nicoletti GF; Napoli C Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34726251 [TBL] [Abstract][Full Text] [Related]
37. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376 [TBL] [Abstract][Full Text] [Related]
38. Circulating tumor DNA: current challenges for clinical utility. Dang DK; Park BH J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177 [TBL] [Abstract][Full Text] [Related]
39. Liquid biopsy in breast cancer: A comprehensive review. Alimirzaie S; Bagherzadeh M; Akbari MR Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931 [TBL] [Abstract][Full Text] [Related]
40. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Postel M; Roosen A; Laurent-Puig P; Taly V; Wang-Renault SF Expert Rev Mol Diagn; 2018 Jan; 18(1):7-17. PubMed ID: 29115895 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]